Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy.
about
ATP-dependent chromatin remodeling complexes as novel targets for cancer therapyAssociation of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeFlavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoidsThe silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumorsModulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic typeTwo BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.Epigenomic regulation of oncogenesis by chromatin remodeling.Identifying targets for the restoration and reactivation of BRM.Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.BRM polymorphisms, pancreatic cancer risk and survival.Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.Induction of functional Brm protein from Brm knockout miceBRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.
P2860
Q26849467-F8D632C7-E8BE-43D5-85A9-9C548C4B52ABQ33709588-ACB81913-E2AC-4E2F-8B09-8F1061E6FFFEQ34260197-3781E585-985B-4DFF-821C-AB864ADAE27CQ34423814-81C5DC5D-3514-44E1-BF64-D7988837C130Q34459131-61DB2EF9-BA46-4B6D-A65D-DBC170552C5FQ36103995-0B5CC197-779A-4AB8-A86C-3F08CC6E63A2Q36420683-70870093-DBFF-4C89-AB08-9FD6793E577FQ37703407-86E59DE9-F031-4D81-864E-A4EFA5F72FFBQ38366100-54A1A69E-622D-4B25-A5B8-8C9A4B9AB478Q38379487-F6A2DA90-FA3E-4B6D-A0F3-E3573FF2D9B6Q38709544-2BD1465A-1D84-4CEE-8849-D47AF27A66E5Q39176522-F9795848-B535-40D7-89DA-1CE816E0274DQ39209851-00A12307-B127-4F5D-A867-1C2704FA4CC4Q40637783-3EC0F227-2FF6-45AA-BC93-F86477BCC8FBQ41703426-BF0077B4-EC23-4B16-8DF1-65C73FB5BE0DQ41857096-4073FDD4-8F14-4D82-BF9F-A4609ADB46F1Q42774884-646AEA8A-9847-46BC-B4C9-A5B6B1162089Q47684416-F0E15ED3-D5A3-47C5-BF77-861A5CDEA278Q47823236-C4DF5A47-E2B0-4A2D-8EF1-755E1E388014Q48231360-CB7644DA-D2F5-4F45-AB8B-5BB27AF11D71Q48368561-4883B847-89C7-40D7-BA9B-29B7D11DD390
P2860
Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacologic reversal of epig ...... l targeted treatment strategy.
@en
type
label
Pharmacologic reversal of epig ...... l targeted treatment strategy.
@en
prefLabel
Pharmacologic reversal of epig ...... l targeted treatment strategy.
@en
P2093
P2860
P356
P1433
P1476
Pharmacologic reversal of epig ...... l targeted treatment strategy.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2011.80
P407
P50
P577
2011-04-11T00:00:00Z
P5875
P6179
1046838795